Janet Mertz | UW Laboratory of Genetics
My UW        Grad School        CALS        SMPH        UW Madison

Janet Mertz










Professor of Oncology


Ph.D., Stanford University, 1975
Postdoctoral Research: MRC Laboratory of Molecular Biology, Cambridge, England



Address: 713A McArdle
Telephone: 262-2383
E-mail: mertz@oncology.wisc.edu

Research Interests:

Transcriptional regulation in DNA tumor viruses and breast cancer

Research Fields:

Cancer Genetics
Gene Expression
Microbial Genetics

Research Description:

One of our group's long-term interests involves regulation of gene expression and mechanisms of oncogenesis by DNA tumor viruses implicated in a variety of human cancers. Recently, we have identified the cellular transcription factor ZEB-1 as a key player in establishment and maintenance of latency following primary infection, reactivation out of latency and, possibly, malignant transformation of cells by the human herpes virus Epstein-Barr virus. These studies could lead to the development of new ZEB-based therapies for the treatment of EBV-associated diseases such as infectious mononucleosis, nasopharyngeal carcinoma, and some lymphomas.

Our group's second area of research concerns the roles of the human estrogen-related receptor a (ERRalpha) in regulation of estrogen responsiveness and breast carcinogenesis. We have found that ERRalpha can function as either a down-modulator or a constitutive activator of estrogen response element-directed transcription, with its activity regulated in part by post-translational phosphorylations occurring via EGFR/ErbB2 (HER2) signaling pathways. ERRalpha-positivity has been shown to be associated with poor prognosis and tamoxifen resistance in breast cancer. This finding is likely due to the active form of ERRalpha substituting for estrogen receptor to activate genes regardless of the presence of ligands. We are currently working to develop reagents that specifically detect the activator form of ERRalpha in primary breast tumors for use in prognosis and determination of best currently available therapeutic options for treatment of individual breast cancers. We also hope to identify drugs that can interfere with ERRalpha's functional activities for use as a novel therapy, especially for the treatment of ER-negative and tamoxifen-resistant breast cancers for which there are currently a paucity of good therapeutic options.

Representative Publications:

Iempridee, T., Das, S., Xu, I.,and Mertz J.E Transforming Growth Factor {beta}-Induced Reactivation of Epstein-Barr Virus Involves Multiple Smad-Binding Elements Cooperatively Activating Expression of the Latent-Lytic Switch BZLF1 Gene. J Virol. Aug;85(15):7836-48, 2011.

Yu, X., McCarthy, P.J., Lim, H.J., Iempridee, T., Kraus ,R.J., Gorlen, D.A., and Mertz J.E. (2011)  The ZIIR element of the Epstein-Barr virus BZLF1 promoter plays a central role in establishment and maintenance of viral latency . J Virol.  May;85(10):5081-90, 2011.

Ellis, A. L., Iempridee, T., Xu, I., and Mertz, J. E.  Cellular MicroRNAs 200b and 429 Regulate the Epstein-Barr Virus Switch Between Latency and Lytic Replication. J Virol. Oct;84(19):10329-43, 2010.

Berg, P., and Mertz, J. E.  Personal Reflections on the Origins and Emergence of Recombinant DNA Technology.  Genetics, 184:  9-17, 2010.

Ellis, A. L., Wang, Z., Yu, X., and Mertz, J. E.  Either ZEB1 or ZEB2/SIP1 Can Play a Central Role in Regulating the Epstein-Barr Virus Latent-Lytic Switch in a Cell-Type-Specific Manner.  J. Virol., 84: 6139-6152, 2010.

Ellis-Connell, A. L., Iempridee, T., Xu, I., and Mertz, J. E.  Cellular MicroRNAs 200b and 429 Regulate the Epstein-Barr Virus Switch Between Latency and Lytic Replication.  J. Virol., in press, 2010 [Epub ahead of print Jul 28, 2010].

Hagemeier, S. R., Dickerson, S. J., Meng, Q., Yu, X., Mertz, J. E., and Kenney, S. C.  Sumoylation of the Epstein-Barr Virus BZLF1 Protein Inhibits Its Transcriptional Activity and Is Regulated by the Virus-Encoded Protein Kinase.  J. Virol., 84: 4383-4394, 2010.

Das, S., Becker, B. N., Hoffmann, F. M., and Mertz, J. E.  Complete Reversal of Epithelial to Mesenchymal Transition Requires Inhibition of Both ZEB Expression and the Rho Pathway.  BMC Cell Biol., 10:94, 2009. 

Hyde, J. S., and Mertz, J. E.  Gender, Culture, and Mathematics Performance.  Proc. Natl. Acad. Sci. USA, 106: 8801-8807, 2009.

Mertz, J. E.  Why Females Remain Underrepresented in Mathematics at the Highest Level.  Am. Soc. Cell Biol. Newsletter, pp. 7-9, August 2009.

Andreescu, T., Gallian, J. A., and Mertz, J. E.  Identifying and Cultivating Extraordinary Mathematical Talent.  Teachers College Record, November 26, 2008. 

Andreescu, T., Gallian, J. A., Kane, J. M., and Mertz, J. E.  Cross-Cultural Analysis of Students with Exceptional Talent in Mathematical Problem Solving.  Notices of the AMS, 55: 1248-1260, 2008.

Ariazi, E. A., Kraus, R. J., Farrell, M. L., Jordan, V. C., and Mertz, J. E.  Estrogen-Related Receptor a1 Transcriptional Activities Are Regulated in Part via the ErbB2/HER2 Signaling Pathway.  Mol. Cancer Res., 5:  71-85, 2007.

Feng, W.-h., Kraus, R. J., Dickerson, S. J., Lim, H. J., Jones, R. J., Yu, X., Mertz, J. E., and Kenney, S. C.  ZEB1 and c-Jun Levels Contribute to the Establishment of Highly Lytic Epstein-Barr Virus Infection in Gastric AGS Cells.  J. Virol., 81:  10113-10122, 2007.

Vu, E. H., Kraus, R. J., and Mertz, J. E.  Phosphorylation-Dependent Sumoylation of Estrogen-Related Receptor a1.  Biochemistry, 46:  9795-9804, 2007.

Yu, X., Wang, Z., and Mertz, J. E.  ZEB1 Regulates the Latent-Lytic Switch in Infection by Epstein-Barr Virus.  PLoS Pathog., 3:e194, 2007.